WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016055935) COMBINATION OF LYSINE-SPECIFIC DEMETHYLASE 1 INHIBITOR AND THROMBOPOIETIN AGONIST
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/055935    International Application No.:    PCT/IB2015/057637
Publication Date: 14.04.2016 International Filing Date: 06.10.2015
IPC:
A61K 45/06 (2006.01), A61K 31/4152 (2006.01), A61K 31/445 (2006.01), A61P 35/00 (2006.01), A61P 35/02 (2006.01)
Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED [GB/GB]; 980 Great West Road Brentford Middlesex TW89GS (GB)
Inventors: ERICKSON-MILLER, Connie L.; (US).
KRUGER, Ryan G.; (US).
STONE, Nicole Lee; (US)
Priority Data:
62/060,156 06.10.2014 US
Title (EN) COMBINATION OF LYSINE-SPECIFIC DEMETHYLASE 1 INHIBITOR AND THROMBOPOIETIN AGONIST
(FR) COMBINAISON D'INHIBITEUR DE DÉMÉTHYLASE 1 SPÉCIFIQUE À LA LYSINE ET D'AGONISTE DE THROMBOPOÏÉTINE
Abstract: front page image
(EN)The present invention relates to a method of treating cancer and pre-cancerous syndromes in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 4- ((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid, or a pharmaceutically acceptable salt thereof, and 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazin o]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
(FR)La présente invention concerne un procédé de traitement de cancer et de syndromes précancéreux chez un patient humain, ainsi que des combinaisons pharmaceutiques utiles dans le cadre d'un tel traitement. En particulier, le procédé concerne un procédé de traitement de cancer qui consiste à administrer 4-((4-((((1R,2S)-2-phénylcyclopropyl)amino)méthyl)pipéridin-1-yl)méthyl)acide benzoïque, ou un sel pharmaceutiquement acceptable de celui-ci, et 3'-[(2Z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4H-pyrazol-4-ylidène]hydrazin o]-2'-hydroxy-[1,1'-biphényl]-3-acide carboxylique, ou un sel pharmaceutiquement acceptable de celui-ci, à un être humain en ayant besoin.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)